Boehringer Ingelheim Korea to market Parkinson's drug

Published: 2004-08-02 06:55:00

Updated: 2004-08-02 06:55:00

Following the merger between Pfizer and Pharmacia, Boehringer Ingelheim Korea is soon expected to exclusively market Mirapex (pramipexole dihydrochloride), which can be used to treat patients who have idiopathic Parkinson's disease in early and advanced states of the disease.

The company said ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK